Clovis slides on rociletinib data, keeps pace with AstraZeneca
This article was originally published in Scrip
Executive Summary
Clovis Oncology saw its stock slide 10.2% on 19 November based on updated results from the Phase II portion of the ongoing TIGER-X Phase I/II clinical trial for its next generation epidermal growth factor receptor (EGFR) inhibitor rociletinib (CO-1686) in many lung cancer patients with a T790M mutation and some patients who don't have the treatment-resistant mutation.